Gastroschisis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Gastroschisis is a congenital anomaly characterized by a full-thickness defect in the abdominal wall near the umbilicus, allowing the protrusion of the intestines. It is uncommonly associated with genetic disorders. Unlike other similar conditions, the exposed bowel in gastroschisis lacks a protective membrane, leading to adhesion, dilation, and inflammation of the intestines. Infants with this condition often experience restricted intrauterine growth. Diagnosis is typically made during a 20-week ultrasound when freely floating bowel loops are observed within the uterus. Pregnancies affected by gastroschisis show elevated maternal serum alpha-fetoprotein (AFP) levels. In contrast to other prenatal abdominal wall defects such as omphalocele, only a small percentage (10%) of gastroschisis cases are accompanied by malformations outside the gastrointestinal tract. Infants with gastroschisis can be categorized as either simple or complex, which helps determine their prognosis and guide their care. The complexity classification is based on the presence or absence of complications like intestinal atresia, stenosis, perforation, necrosis, malrotation, or volvulus. The exact cause of gastroschisis is not fully understood. It arises due to a failure in the development and formation of the ventral body wall during embryogenesis, leading to the herniation of the intestines. Several factors have been implicated in the development of gastroschisis, including tobacco use, specific environmental exposures (such as nitrosamines and atrazine), the use of cyclooxygenase inhibitors (such as aspirin and ibuprofen), and certain decongestants (such as pseudoephedrine and phenylpropanolamine). The formation of the abdominal wall occurs during the fourth week of gestation, progressing in the craniocaudal and mediolateral directions. In the sixth week, the liver and midgut herniate through the umbilical cord, followed by the midgut returning to the abdominal cavity by the tenth week after completing the rotation. It generally has a more favorable prognosis, with excellent long-term outcomes, compared to other abdominal wall defects. The overall survival rate for live-born infants with gastroschisis is 98 percent. Infants with gastroschisis are more likely to be born prematurely (28% compared to 6% in unaffected infants). Complications can arise in infants with gastroschisis due to the need for total parenteral nutrition (TPN) and the associated risk of line sepsis, the configuration of the bowel leading to necrotizing enterocolitis (NEC), and infections of the abdominal wound resulting from gastroschisis closure.
·
The incidence of gastroschisis in the United
States (US) has increased, with an estimated incidence of 4.6 per 10,000 live
births.
Thelansis’s “Gastroschisis Market Outlook,
Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Gastroschisis treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
KOLs insights
of Gastroschisis across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Gastroschisis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment